Immunoscore® CR 4 types of assays

Immunohistochemistry + sophisticated algorithm + advanced image analysis

Part of IMMUNOGRAM, IMMUNOSCORE® Clinical Research (CR) includes 4 types of assays which combine immunohistochemistry (up to 7 biomarkers on a single FFPE slide), sophisticated algorithm and advanced image analysis

IMMUNOSCORE®CR allows to accurately measure T cell infiltration and exhaustion, tumor sensitivity to cytotoxic T cells and the impact of immune suppressive cells, notably MDSC.


IMMUNOSCORE®CR TL (T lymphocytes) accurately quantifies T cell infiltrate, in and around the tumor, in a variety of cancer types to distinguish between cold, altered, and hot tumors (Galon J. et al, 2016; Pagès et al,2009; Berghoff et al., 2016; Pagès et al., 2018).

Developed and adapted from the algorithm of the IMMUNOSCORE ® IVD test for localized Colon Cancer, IMMUNOSCORE®CR TL measures the density of CD8+ & CD3+ T cells of resected or biopsied cancer samples.   please visit IMMUNOSCORE® IVD test


Based on the concomitant detection of a relevant Immune Checkpoint (IC) and CD8 T cells, the test analyses density, proximity and clustering of the two cell populations to predict the response to IC modulation.

In the context of PD-1/PD-L1 blockade, IMMUNOSCORE®CR IC allows on a single slide, the precise quantification of positive CD8+ cells and whole PD-L1+ cells (cells/mm²) but also cells clustering and proximity index. It therefore provides an accurate assessment of the two cell populations (Monville F. et al., 2017).


IMMUNOSCORE® IC is available and CE-IVD for NSCLC (Non-Small Cell Lung Cancer).   please visit IMMUNOSCORE® IC IVD test


This assay reveals exhausted T cells by combining the detection of CD3 and CD8 T lymphocytes with a panel of IC. Combined with clinical information, this powerful set of data is used to help understanding drug’s mechanism of action and resistance to IC modulators.

IMMUNOSCORE®CR TCE is based on IHC multiplex technology (Brightplex), an automated workflow that takes advantage of brightfield microscopy to accurately analyze up to 7 biomarkers simultaneously on a single slide and identify complex immune cells phenotypes. Basically, specific immune cell populations can be precisely quantified and spatially localized in specific region of interest of the tissue (tumor, invasive margin, stroma, parenchyma).


More info on Brightplex technology here


This range of tests includes panel of biomarkers for a precise identification of Suppressor Cells (SC) within the tumor microenvironment (TME).

Example panel: polymorphonuclear and monocytic Myeloid-Derived Suppressor Cells (PMN- & M-MDSC).

MDSC limit T and NK cells anti-cancer responses and promote angiogenesis and tumor invasion.

IMMUNOSCORE® CR SC reveals the impact of MDSC within the TME and their prognostic and predictive value.

Another example is the test IMMUNOSCORE® CR T Reg based on the detection of CD4 and FOXP3 and using image analysis to identify the Treg population into the tumor microenvironment.

Other indications on existing panels or additional panels can be available on demand.


More info on Brightplex technology here


Galon J and Bruni D

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Nat Rev Drug Discov. 2019


More info

Angelova M et al.

Evolution of Metastases in Space and Time under Immune Selection

Cell. 2018


More info

Pagès et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

The Lancet, 2018

May 10, 2018

More info

Mlecnik B et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst. 2018 ;

Jan 1;110(1). doi: 10.1093

More info

Berghoff AS et al.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Oncoimmunology 2016 ;

Jun 9;5(1):e1057388

More info

Kirilovsky A et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients

Int Immunol. 2016

doi: 10.1093/intimm/dxw021

More info

Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon

Journal for ImmunoTherapy of Cancer 2016

DOI: 10.1186/s40425-016-0161-x

More info

Galon J et al

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

2016 ASCO Annual Meeting

J Clin Oncol 34, 2016 (suppl; abstr 3500)

More info

Mlecnik B et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Immunity. 2016 ;

Mar 15;44(3):698-711.

More info

Mlecnik B et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med. 2016 ;

24 Feb 2016, Vol. 8, Issue 327, pp. 327ra26.

More info

Galon J et al.

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

J Pathol. 2014


More info

Galon J et al.

Cancer classification using the Immunoscore: a worldwide task force.

J Transl Med 2012 ;

10 : 205.

More info

Mlecnik B et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

J Clin Oncol 2011 ;

29 : 610-8.

More info

Pagès F al.

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

J Clin Oncol 2009 ;

27 : 5944-51.

More info

Galon J et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Science 2006 ;

313 : 1960-4.

More info

Interested in Immunoscore® CR ? Contact us

Our IO Scoring Services

HalioDx newsletter subscription

Join our newsletter and be the first to get notified on new updates.

× Hide this popup.